

Erratum to: Vedolizumab in moderately to severely active ulcerative colitis or Crohn's disease: a guide to its use

Katherine A. Lyseng-Williamson¹

Published online: 11 July 2016
© Springer International Publishing Switzerland 2016

Erratum to: Drugs Ther Perspect (2016)
32(6):265–75
DOI 10.1007/s40267-016-0311-8

Page 267, Table 1, 'How should it be administered?' section, 'Restarting treatment after interruption' subsection: the cell entry in column 2, which previously read:

"EU/USA: consider administering every 4 weeks"

Should read:

"EU: consider administering every 4 weeks".

The online version of the original article can be found under
doi:[10.1007/s40267-016-0311-8](https://doi.org/10.1007/s40267-016-0311-8).

✉ Katherine A. Lyseng-Williamson
dtp@adis.com

¹ Springer, Private Bag 65901, Mairangi Bay, 0754 Auckland,
New Zealand